PGP and atrial fibrillation: The dosage is reduced to 30 mg if a patient has a low body weight (≤60 kg), has low creatinine clearance (CrCl ≤ 50 mL/min), or takes a concomitant P-glycoprotein (P-gp) inhibitor.5The Edoxaban Low-Dose for EldeR CARE AF patients (ELDERCARE-AF) study6was a randomized placebo-controlled study in which the efficacy and safety of edoxaban 15 mg once daily versus placebo were evaluated in Japanese patients with nonvalvular AF (NVAF) aged ≥80 years who were ineligible for standard oral anticoagulant therapy.